The role of allopregnanolone in postpartum depression

The role of allopregnanolone in postpartum depression - The role of allopregnanolone in postpartum depression

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000054603

Enrollment

Registered

2024-06-13

Start date

2024-06-30

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

postpartum depression

Interventions

None listed

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Those who are already participating in research on postpartum hair loss. Those who have given informed consent.

Exclusion criteria

Exclusion criteria: Those who do not consent to informed consent.

Design outcomes

Primary

Measure	Time frame
Serum concentrations of progesterone metabolites (pregnenolone, progesterone, 5alpha-dihydroprogesterone, allopregnanolone) at late pregnancy (around 36 weeks of pregnancy), immediately after delivery (3-6 days after delivery), 3 months and 5 months after delivery, when postpartum depression is most likely to occur. Edinburgh Postnatal Depression Questionnaire(EPDS), Athens Insomnia Scale(AIS), and Brief-type self-administered diet history questionnaire (BDHQ) at the same time points.	—

Measure

Time frame

Serum concentrations of progesterone metabolites (pregnenolone, progesterone, 5alpha-dihydroprogesterone, allopregnanolone) at late pregnancy (around 36 weeks of pregnancy), immediately after delivery (3-6 days after delivery), 3 months and 5 months after delivery, when postpartum depression is most likely to occur. Edinburgh Postnatal Depression Questionnaire(EPDS), Athens Insomnia Scale(AIS), and Brief-type self-administered diet history questionnaire (BDHQ) at the same time points.

—

Countries

Japan

Contacts

Public ContactAsuka Hirose

Tokyo Medical and Dental University Department of Obstetrics and Gynecology

a-kacrm@tmd.ac.jp03-5803-5322

Outcome results